From patent cliffs and government price controls, to self-pay models and staff-model HMOs, a look at the forces that could deflate the bubble—and those factors likely to keep it afloat a while longer.

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

Advice for pharma distributors and dispensers on what they should do now in order to solidify a secure supply chain.

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead

Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - October 2025

Cencora executive Heather Zenk discusses how innovations in cold chain, data visibility, and sustainability strategies are transforming the drug delivery process.

Building Resilient, Sustainable Pharma Supply Chains

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the second part of his Pharma Commerce video interview, Shawn Opatka, VP and GM, Honeywell Life Sciences, notes that nearly all pharma organizations are experimenting with AI to address labor shortages, data challenges, and regulatory demands, but full-scale adoption remains on the horizon as companies balance innovation with compliance.

Pharma Accelerates AI Adoption as Transparency and Traceability Take Center Stage

Articles

The appellate court upheld Medicare’s authority to negotiate lower drug prices under the Inflation Reduction Act, following similar rulings against AstraZeneca, Bristol Myers Squibb, and Novartis.

Third Circuit Court Rejects Novo Nordisk Challenge to Inflation Reduction Act

Krenar Komoni, founder and CEO of Tive, explains how the pharmaceutical industry’s transition from passive to real-time temperature control creates short-term challenges but will ultimately enable AI-driven automation, lower costs, higher quality, and better customer experiences.

LogiPharma USA 2025: How the Pharmaceutical Industry Collaborates to Boost Resilience Across the Global Supply Network

Podcasts

This episode of Pharma Pulse covers the FDA’s approval of golimumab for pediatric ulcerative colitis, AstraZeneca’s new multi-target neuroscience partnership with Algen, and Peli BioThermal’s acquisition of Evo to strengthen its global cold chain portfolio.

Pharma Pulse: FDA Expands Pediatric UC Treatment Options, AstraZeneca and Algen Partner in Neurology, and Peli BioThermal Boosts Cold Chain Capabilities

As precision medicine reshapes drug distribution, Ammie McAsey, SVP of Supply Chain Operations, McKesson, highlights the need for deeper investments in technology, temperature control, and end-to-end visibility to ensure quality and patient safety in advanced therapy supply chains.

LogiPharma USA 2025: Advanced Therapies Push Pharma Supply Chains Beyond Speed 

Has over 15 years of experience in the life sciences industry. Until recently, Jayanthi was with ICON Plc as a global business intelligence manager.

Life sciences organizations have an opportunity to move beyond patient-centered care and embrace a model that values lived experience, fosters collaboration, and positions patients as active contributors to research, treatment, and innovation.

Empowering Patients as Partners: The Next Frontier for Pharma Companies

The addition of Evo’s cryogenic shipping and tracking technology enhances Peli BioThermal’s reach across the pharma value chain, driving innovation and integration in temperature-controlled logistics while supporting these therapies.

Peli BioThermal Expands Cold Chain Portfolio With Evo Acquisition to Strengthen CGT Logistics

This first-party approach to data-driven messaging can ensure timely, compliant, and personalized engagement with healthcare providers at the point of care.



Why Your EHR Messaging Must Be Real-Time

As AI adoption accelerates across life sciences, Shawn Opatka, VP and GM of Honeywell Life Sciences, and Linda Malek, partner at Crowell & Moring, discuss how regulatory expectations and federal initiatives—like the White House AI Action Plan—are shaping the technology’s future role in pharma quality, traceability, and healthcare systems.

Pharma’s AI Evolution: Balancing Innovation, Transparency, and Regulation

This episode of Pharma Pulse covers new research showing how obesity at age 20 increases postpartum diabetes risk, Amgen’s new direct-to-consumer digital platform aimed at improving treatment access, and Eli Lilly’s $1 billion investment to strengthen manufacturing in India.

Pharma Pulse: Study Links Early Obesity to Postpartum Diabetes Risk, Amgen Launches AmgenNow, and Eli Lilly Strengthens Global Supply Chain

How can 360° connectivity drive pharma innovation?

Bridging People, Process, and Technology

The investment will establish a new hub overseeing contract manufacturing across India and expand Lilly’s global supply of medicines for Alzheimer’s, diabetes, obesity, and cancer, amid shifting US trade and tariff policies.

Eli Lilly Invests Over $1 Billion to Strengthen Manufacturing and Supply Capabilities in India

In a recent panel discussion, Krenar Komoni, founder and CEO of Tive, highlighted how combating rising supply chain theft requires a multi-layered, technology-driven security strategy. 

LogiPharma USA 2025: Pharmaceutical Supply Chain Security

This episode of Pharma Pulse covers allegations of retaliation against a former NIAID director following whistleblower complaints, new research suggesting ALS may be an autoimmune disease, and the wave of hospital layoffs affecting thousands of healthcare workers across the United States.

Pharma Pulse: NIAID Whistleblower Controversy, ALS Linked to Autoimmunity, and Hospital Layoffs Accelerate Nationwide

Ammie McAsey, SVP of Supply Chain Operations, McKesson, emphasizes the critical role of collaboration, technology, and partnerships in ensuring advanced and specialty therapies reach patients safely and effectively.

LogiPharma USA 2025: Collaboration Takes Center Stage in Specialty Therapy Supply Chains

Cencora executive Heather Zenk discusses how innovations in cold chain, data visibility, and sustainability strategies are transforming the drug delivery process.


A new report underscores how 2D barcodes and automated data capture powered by GS1 standards can help logistics and life sciences companies overcome outdated systems, labeling issues, and visibility gaps.

GS1 US Pushes for Intelligent Data Capture to Strengthen Supply Chain Efficiency and Transparency

As the sentiment of surveyed dangerous goods experts backs up, updated packaging pursuits can boost efficiency and cut costs—while mitigating the environmental impact. 

Greener, Smarter, and Less Expensive: How Pharma Packaging is Evolving

Dave Malenfant, healthcare supply chain expert, outlines the topics that are top of mind at the show.

LogiPharma USA 2025: What Were the Standout Trends?

This episode of Pharma Pulse covers the FDA’s quiet approval of the first generic mifepristone tablet, Takeda’s decision to discontinue cell therapy research programs, and SciSafe’s expansion of biopharma storage capacity with a new East Brunswick, New Jersey facility.

Pharma Pulse: FDA Approves First Generic Mifepristone, Takeda Exits Cell Therapy Research, and SciSafe Expands Biopharma Storage

Senior Vice President, Market Development, at ConnectiveRx.

Amid intensified competition—and evolving IRA and PBM dynamics—leaders in the access space must now adopt a strategist mindset. 

Hubs as Revenue Protection: Rethinking Patient Access in the Era of Disruption 

The new 5-million-cubic-foot biorepository enhances cold chain logistics, expands biopharma storage capacity, and strengthens New Jersey’s position as a life sciences hub.

SciSafe Expands Biopharma Storage With New East Brunswick Facility

Founder and Principal Consultant at 1st Line Partners.

Companies must assess illicit trade risks under a new EU directive, making materiality and compliance critical for sustainability reporting.

To Be or Not to Be Material? That is the Question

Dave Malenfant, healthcare supply chain expert, reflects on LogiPharma USA’s 20-year evolution, noting its shift toward greater diversity and inclusion, particularly with more women entering the industry.

LogiPharma USA 2025: The Conference's Development Over 20 Years

This episode of Pharma Pulse covers the potential ramifications of a federal government shutdown on FDA operations, Aetna’s newly announced 2026 Medicare Advantage offerings, and new research showing maternal and child mortality rates in the US remain higher than in most high-income nations.

Pharma Pulse: FDA Faces Shutdown Risks, Aetna Unveils 2026 Medicare Advantage Plans, and US Maternal Mortality Remains High

Following Congress’ failure to pass funding measures, FDA announced it will continue only essential public health and safety functions. This amid a pause on imposing 100% tariff rates.

FDA Operations Scale Back Amid Government Shutdown, Halting New Drug Application Reviews

Marketed as cost-saving tools, AFPs can also strain safety-net resources.


Alternative Funding Programs Threaten Patient Access

Experts from Moderna, Revelation Pharma, and Alexion offer ways to reduce risks, improve real-time visibility, and ensure product integrity in the growing ship-to-home market.

LogiPharma USA 2025: How Pharma Leaders Are Tackling Temperature Monitoring in Direct-to-Patient Shipments

Amid pressures on pharma to match the lowest international prices, experts warn of “policy laundering” and discriminatory impact.

Inside the MFN Pricing Actions

Dave Malenfant, healthcare supply chain expert, shares his excitement about the strong turnout at LogiPharma USA, noting a packed master class and his role as chair of the “people” track—a personal passion.

LogiPharma USA 2025: Dave Malenfant's Sneak Peek

This episode of Pharma Pulse covers ATA’s warning that telehealth protections are critical to maintaining care access during a potential federal shutdown, new KFF data showing the rapid rise of Medicare Advantage special needs plans, and Halozyme’s $750 million acquisition of Elektrofi to expand its drug delivery portfolio.

Pharma Pulse: Telehealth Access at Risk During Shutdown, Medicare Advantage SNPs Surge, and Halozyme Buys Elektrofi for $750M

How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of proactive chemistry, manufacturing, and controls strategies.

How Cell and Gene Therapy Developers Can Reduce Risk of FDA Complete Response Letters With Proactive CMC Strategies

Dave Malenfant, healthcare supply chain expert, discusses the ramifications of a 100% tariff on branded and patented drugs entering the US.

LogiPharma USA 2025: Ramifications of a 100% Tariff on Branded and Patented Drugs Entering The US

Bayer’s Luiz Barberini highlights how artificial intelligence is transforming supply chain operations, while emphasizing the irreplaceable value of trust, transparency, and human relationships.

LogiPharma USA 2025: Balancing AI and Human Connection in Pharma Supply Chains

This episode of Pharma Pulse covers the Trump administration’s plan to launch a government-run healthcare website for patients, new data showing gabapentin has become the fifth most prescribed drug in community pharmacies, and promising trial results from a novel gene therapy that slows the progression of Huntington’s disease.

Pharma Pulse: Trump Plans Direct-to-Patient Website, Gabapentin Prescriptions Surge, and Gene Therapy Slows Huntington’s Progression

Supply chain leaders share strategies to address persistent drug shortages, highlighting vulnerabilities, manufacturing complexities, and the importance of cross-industry collaboration.

LogiPharma USA 2025: Strategies to Mitigate Drug Shortages

At the conference’s milestone 20th anniversary event in Boston, experts unpacked the final stages of DSCSA implementation, highlighting pharmacy compliance challenges, state-level variability, and the role of technology in securing the pharmaceutical supply chain.

LogiPharma USA 2025: Determining DSCSA Readiness

This episode of Pharma Pulse covers new data showing measles vaccine coverage remains below herd immunity thresholds, the FDA’s approval of guselkumab for pediatric plaque psoriasis and psoriatic arthritis, and AbbVie breaking ground on a new API manufacturing site in Illinois.

Pharma Pulse: Measles Vaccination Gaps Persist, FDA Approves Guselkumab for Children, and AbbVie Expands US Manufacturing

This guide shows how to move beyond rear-view reporting and transform data into actionable strategies that drive payer engagement, sharpen planning, and maximize brand performance.

Turning Data Into a Strategic Advantage

How is AI solving pharma's speed-to-market challenge?

Accelerating Personalization

This episode of Pharma Pulse covers the Trump administration’s 100% tariff on branded drug imports, new research linking pediatric influenza to neurological complications amid vaccination gaps, and AbbVie’s FDA submission for tavapadon, a potential new treatment for Parkinson’s disease.

Pharma Pulse: Drug Tariffs Threaten Access, Pediatric Flu Raises Vaccination Concerns, and AbbVie Files NDA for Tavapadon

Beginning Oct. 1, the US will impose a 100% tariff on branded and patented pharmaceutical imports unless manufacturers are actively building domestic production facilities, a move aimed at reshoring drug manufacturing.

Trump Announces 100% Tariff on Branded Drugs Unless Pharma Builds US Plants

Capturing insights from executives and industry experts on the biggest challenges shaping pharma today, from drug pricing pressures and access barriers to supply chain shifts, digital adoption, and evolving patient-centered care strategies.

Pharma Commerce's 2025 State of the Industry Survey

This episode of Pharma Pulse covers new research showing Medicaid cuts could widen pediatric coverage gaps, clinical trial data on a fixed-dose combination therapy lowering heart failure risk in type 2 diabetes, and Bristol Myers Squibb’s launch of a direct-to-patient program for Sotyktu to improve psoriasis treatment access.

Pharma Pulse: Medicaid Cuts Threaten Childhood Coverage, Fixed-Dose Combo Reduces Heart Failure in Diabetes, and BMS Expands Sotyktu Access

Through its “BMS Patient Connect” platform, the company is lowering out-of-pocket costs and providing nationwide shipping, making the treatment for affordable and accessible for US patients.

Bristol Myers Squibb Expands Direct-to-Patient Access With New Sotyktu Program

Ullrich Mayeski, community engagement director of health with GS1 US, emphasizes the critical need to address interoperability challenges at the dispenser level, ranging from small independent pharmacies to large hospital systems. 

HDA 2025 Traceability Seminar: Closing Gaps in Pharma’s Supply Chain

This episode of Pharma Pulse covers the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations for all adults, new data showing the Medicare Part D Senior Savings Model lowers insulin costs and improves care, and Eli Lilly’s investment in a new Houston manufacturing facility to support its fast-growing pipeline.

Pharma Pulse: CDC Expands COVID-19 Vaccine Guidance, Medicare Model Cuts Insulin Costs, and Lilly Invests in Houston Facility

Ullrich Mayeski, community engagement director of health with GS1 US, outlines how manufacturers, distributors, and dispensers can strengthen end-to-end traceability. 

HDA 2025 Traceability Seminar: Building a Secure and Interoperable Supply Chain

The Generation Park site will create over 600 permanent jobs, support advanced small molecule production, and play a role in scaling orforglipron, Lilly’s first oral GLP-1 receptor agonist for obesity.

Eli Lilly to Invest $6.5 Billion in New Houston Manufacturing Facility

This episode of Pharma Pulse covers the FDA’s review of a possible link between prenatal acetaminophen use and autism, GSK’s supplemental new drug application to update leucovorin labeling, and Celltrion’s acquisition of an Eli Lilly production facility to expand biologics manufacturing capacity.

Pharma Pulse: FDA Examines Prenatal Acetaminophen Risks, GSK Files sNDA for Leucovorin, and Celltrion Buys Lilly Plant

Ullrich Mayeski, community engagement director of health with GS1 US, explains how with over a decade of collaboration, manufacturers and distributors are largely prepared for DSCSA compliance. The remaining challenge lies in ensuring consistent readiness across dispensers, while maintaining open communication throughout the supply chain.

HDA 2025 Traceability Seminar: Pharma Industry Shows Strong Readiness for DSCSA Enforcement

The South Korean pharma company’s US subsidiary is purchasing Eli Lilly’s Branchburg, NJ site to safeguard against potential tariffs. strengthen domestic production, and expands its biosimilar footprint.

Celltrion to Acquire Eli Lilly’s $330M Production Plant

This episode of Pharma Pulse covers ACIP’s move toward shared decision-making for COVID-19 vaccines, Pfizer’s acquisition of Metsera to strengthen its obesity and cardiovascular pipelines, and Closed Loop Medicine’s partnership with Wedosify to improve patient adherence to GLP-1 therapies.

Pharma Pulse: CDC Shifts COVID-19 Vaccine Guidance, Pfizer Buys Metsera for Obesity Pipeline, and New Tech Targets GLP-1 Adherence

Ullrich Mayeski, community engagement director of health with GS1 US, describes the organization’s EPCIS standard for meeting DSCSA requirements while underscoring that true supply chain success depends on robust data quality practices, clear procedures, and cross-team accountability to ensure patients receive their medications without disruption.

HDA 2025 Traceability Seminar: Data Quality and EPCIS Standards Take Center Stage 

The platform enables clinicians to tailor GLP-1 titration at scale, aiming to reduce discontinuation rates and improve long-term outcomes for patients undergoing obesity treatment.

Closed Loop Medicine Debuts WeDosify in US to Personalize GLP-1 Dosing and Improve Patient Adherence

This episode of Pharma Pulse covers the CDC’s decision to postpone changes to Hepatitis B vaccine guidance, new research showing value-based care improves visit frequency and consistency for seniors, and Takeda’s partnership with VELA to launch wind-powered transport for medicines.

Pharma Pulse: CDC Delays Hepatitis B Vaccine Vote, Value-Based Care Improves Senior Access, and Takeda Tests Wind-Powered Shipping

Takeda will be shipping treatments between Europe and the US using VELA’s sailing cargo trimaran, potentially reducing greenhouse gas emissions by up to 99% when compared with air freight.

Takeda Partners with VELA to Launch Wind-Powered Medicine Transport Across the Atlantic

Industry leaders—from manufacturers, distributors, and dispensers—reported increased preparedness for compliance, with discussions shifting toward exception management, governance, and enforcement readiness, note Ullrich Mayeski of GS1 US and Mark Karhoff of Ten Count Consulting.

HDA 2025 Traceability Seminar: Confidence Grows Across Pharma Supply Chain

New bipartisan legislation would give the FDA authority to modernize prescribing information, reducing waste while improving accuracy and patient care.

Congress Revives Push to Digitize Prescription Information

This episode of Pharma Pulse covers GSK’s $30 billion plan to expand US biopharma production, new evidence that weekly GLP-1 therapies significantly reduce cardiovascular risks, and Roche’s acquisition of 89bio to add the FGF21 analog Pegozafermin to its growing metabolic disease portfolio.

Pharma Pulse: GSK Invests $30B in US Manufacturing, GLP-1s Show Heart Benefits, and Roche Buys 89bio for Metabolic Pipeline

The pharmaceutical giant’s commitment includes a $1.2 billion investment in advanced facilities powered by AI and digital technology, strengthening biopharma manufacturing and clinical research across the United States.

GSK Commits $30B to Strengthen US Biopharma R&D and Manufacturing Capacity

This episode of Pharma Pulse covers the former CDC director’s claim she was dismissed for refusing to prioritize ideology over evidence, new findings that physician mental health remains a serious concern, and Eli Lilly’s $5 billion investment in a new Virginia manufacturing plant to expand biologics production.

Pharma Pulse: CDC Leadership Controversy, Physician Mental Health Challenges, and Eli Lilly’s $5B US Manufacturing Expansion

In the final part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, shares how the value in ensuring patients and clinicians have access to accurate resources requires meeting them where they already seek information, with seamless, trustworthy education integrated into their daily workflows.

Education Strategies to Counter Misinformation in Obesity Treatments

The new Goochland County facility will serve as Lilly’s first fully integrated API and drug product site, focusing on antibody-drug conjugates, while creating thousands of jobs and strengthening domestic supply chains.

Eli Lilly to Build $5 Billion Manufacturing Plant in Virginia, Expanding US Biopharma Capacity

This episode of Pharma Pulse covers new data showing 1 in 6 US parents are delaying or skipping childhood vaccinations, Secretary Robert F. Kennedy Jr.’s move to expand a federal vaccine advisory committee, and survey findings that more than half of healthcare workers are considering leaving their current roles.

Pharma Pulse: Parental Vaccine Hesitancy Grows, Federal Vaccine Committee Expands, and Healthcare Workforce Faces Retention Crisis

In the third part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, notes that in a crowded weight management landscape, marketers play a critical role in combating misinformation by ensuring healthcare providers and patients have clear, accurate information on the safety, efficacy, and access pathways of FDA-approved treatments.

Communicating the Value of Approved Therapies

A new JAMA Network Open study highlights how over-the-counter oral contraceptives can reduce barriers to care, especially for uninsured, rural, and adolescent populations, amid shifting federal policies on reproductive health.

A Deep Dive Into FDA’s Approval of First OTC Birth Control Pill 

This episode of Pharma Pulse covers healthcare advocates’ push for a $50 billion Rural Health Transformation Program, new research showing pneumococcal vaccination gaps among adults with celiac disease, and Novartis’ $5.7 billion licensing agreement with Monte Rosa Therapeutics for protein degrader therapies.

Pharma Pulse: Rural Hospitals Seek $50B Lifeline, Vaccination Gaps Found in Celiac Patients, and Novartis Signs $5.7B Licensing Deal

In the second part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, points out that as patient fatigue grows with injectable therapies, oral alternatives are emerging as vital tools for clinicians and patients alike, expanding choice, improving access, and supporting more personalized obesity treatment strategies.

Oral Weight Loss Treatments Offer Patients and Clinicians New Options in Obesity Care

The collaboration seeks to reduce drug waste, prevent errors, and support more reliable delivery of life-saving therapies to patients worldwide.

New Phononic–Peltier Partnership Targets Safer, Smarter Cold Chain for Medicines

This episode of Pharma Pulse covers new FDA guidance to speed development of non-opioid pain treatments, the FTC’s warning against non-compete agreements for doctors and nurses, and DHL Supply Chain’s acquisition of SDS Rx to strengthen last-mile healthcare delivery.

Pharma Pulse: FDA Accelerates Non-Opioid Pain Drug Development, FTC Targets Non-Competes in Healthcare, and DHL Expands Last-Mile Logistics

In the first part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, explains how predictable, affordable pricing models for FDA-approved oral weight loss drugs can reduce barriers to care, improve long-term adherence, and support better outcomes for patients managing chronic obesity.

Consistent Cash-Pay Options Could Transform Access to Obesity Medications

The deal will integrate SDS Rx’s specialized delivery network of US locations into DHL’s Life Sciences & Healthcare division, strengthening same-day and final-mile services as demand for specialty pharma and patient-centered logistics continues to rise.

DHL Supply Chain Acquires SDS Rx, Expanding Last-Mile Healthcare Logistics

This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.

Pharma Pulse: White House Eyes China Drug Restrictions, Pfizer-BioNTech Vaccine Data Strong, and Samsung Biologics Secures US Deal

In the final part of his Pharma Commerce video interview, Boyede Sobitan, Zebra Technologies’ global healthcare strategy lead, details how in a post-COVID landscape, technologies that track and regionalize hospital inventory could become critical tools for state and local health departments, ensuring visibility, preparedness, and smarter resource allocation during future disruptions.

Harnessing Tech to Build Resilient Hospital Supply Chains

The South Korean CDMO has signed its second multi-billion-dollar contract in less than a year, even as shifting US trade policies and looming tariffs create challenges for global drugmakers.

Samsung Biologics Secures $1.3B US Manufacturing Deal Amidst Tariff Uncertainty

Key points from our recent webinar on the President’s MFN order.

What the President’s Drug Pricing Push Means for Pharma, Payers, and Patients

This episode of Pharma Pulse covers Florida’s plan to roll back school vaccine mandates amid a measles outbreak, President Trump’s renewed focus on limiting direct-to-consumer pharma advertising, and ICER’s latest cost-effectiveness analysis of GLP-1 obesity treatments semaglutide and tirzepatide.

Pharma Pulse: Measles Outbreak Spurs Vaccine Mandate Debate, Trump Eyes DTC Ad Restrictions, and ICER Reviews GLP-1 Costs

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for broader coverage and policy solutions.

ICER Releases Cost Analysis Report on Obesity Treatments Semaglutide, Tirzepatide

This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.

Pharma Pulse: Novartis Expands Cardiovascular Pipeline, Flu Severity Drivers Identified in Seniors, and Fixing Medication Nonadherence

In the third part of his Pharma Commerce video interview, Boyede Sobitan, Zebra Technologies’ global healthcare strategy lead, explains why forward-thinking facilities see these tools as key to cutting errors and improving inventory efficiency.

Hospitals Weigh ROI of RFID and RTLS for Smarter Medication Management

The move consolidates R&D, manufacturing, and commercialization under the CGM system’s developer to accelerate growth and expand global reach.

Ascensia to Transfer Eversense CGM Commercial Operations to Senseonics

This episode of Pharma Pulse covers the FDA’s decision to restrict bulk ingredients for compounded GLP-1 therapies, new evidence showing RSV vaccines improve cardiorespiratory outcomes in adults over 60, and pharmacy owners’ concerns over barriers to participating in the Medicaid Drug Price Negotiation Program.

Pharma Pulse: FDA Blocks Compounded GLP-1 Ingredients, RSV Vaccination Benefits Seniors, and Pharmacies Struggle With Pricing Program

In the second part of her Pharma Commerce video interview, Annika Matas, Zebra Technologies’ senior director of product management and business operations, supplies & sensors, shares that from automated RFID cabinets to handheld scanners, hospitals are streamlining inventory tracking, cutting labor costs, and reducing medication loss, especially critical during drug shortages.

Transforming Hospital Pharmacy Inventory Management

By reducing waste, improving forecasting, and strengthening payer negotiations, these  technologies are helping pharmaceutical companies unlock efficiency, accelerate adoption, and differentiate in competitive markets.

Precision Dosing as a Market Strategy: How Model-Informed Tools Drive Cost, Speed and Access

This episode of Pharma Pulse covers Gilead’s groundbreaking on a new technical development hub to accelerate biopharma innovation, the World Health Organization’s decision to add GLP-1s to its Essential Medicines List for diabetes, and new data showing high-dose influenza vaccines reduce heart risks in older adults.

Pharma Pulse: Gilead Expands R&D Hub, WHO Adds GLP-1s to Essential Medicines List, and High-Dose Flu Vaccine Shows Heart Benefits

In the first part of their Pharma Commerce video interview, Boyede Sobitan and Annika Matas of Zebra Technologies warn that ongoing medication shortages are forcing staff to borrow supplies, delay procedures, and divert nurses from patient care to logistical tasks, creating both financial pressures and operational inefficiencies.

How Drug Shortages Could Disrupt Hospital Operations and Strain Patient Care

The new 180,000-square-foot facility in Foster City anchors the company’s long-term $32 billion investment in domestic manufacturing and R&D.

Gilead Breaks Ground on Technical Development Hub to Drive US Biopharma Innovation

This episode of Pharma Pulse covers President Trump’s appeal to the Supreme Court to preserve pharma tariffs, Sanofi’s 10% stock drop after Amlitelimab failed in Phase III, and new research showing how the COVID-19 pandemic reshaped pneumococcal mortality trends.

Pharma Pulse: Trump Appeals Tariff Ruling, Sanofi Shares Slide on Trial Miss, and COVID-19 Alters Pneumococcal Mortality

In the final part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, focuses on physician demand, global momentum, and how US legislation can help the industry finally move beyond paper.

Overcoming Barriers to Full e-Prescribing Adoption

Following a federal appeals court decision that struck down much of his tariff authority under the International Emergency Economic Powers Act, President Trump is asking the Supreme Court to fast-track review. 

Trump Pushes Supreme Court to Save Tariffs After Appeals Court Ruling Limits Presidential Power

Understanding AI's actual role in commercial life sciences operations. 

Smarter, Faster, Bolder: AI’s New Role in Pharma Strategy

This episode of Pharma Pulse covers Amgen’s $600 million investment in a new California R&D center, Novartis’s collaboration with Argo Biopharmaceuticals to boost its cardiovascular pipeline, and new data showing Wegovy outperforming tirzepatide in reducing major adverse cardiovascular events.

Pharma Pulse: Amgen Invests $600M in Innovation Hub, Novartis Collaborates With Argo, and Wegovy Tops Tirzepatide in Heart Outcomes

In the second part of his Pharma Commerce video interview, Diogo Rau, executive vice president and chief information and digital officer for Eli Lilly and Company, highlights that cutting down on the 90 billion sheets of paper used for medicine inserts each year isn’t just an environmental win—it’s also a critical step toward making drug information more accessible for patients with vision challenges, language barriers, or cognitive and physical disabilities.

Featured Content

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead

Pharmaceutical Commerce - October 2025

Building Resilient, Sustainable Pharma Supply Chains